XML 20 R7.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Cash Flows - USD ($)
 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Cash flows from operating activities:    
Net loss $ (136,542,089) $ (162,307,870)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 1,361,595 1,608,060
Amortization of intangible assets 266,874 273,540
Change in fair value of derivative liability 0 110,976,977
Stock-based compensation 15,242,305 7,663,988
Non-cash interest expense 435,445 3,013,942
(Gain) loss on short-term investments (153,252) 576,001
Settlement of receivable with shares of common stock from affiliated entity (PLS) 0 (1,713,770)
Gain on deconsolidation of Geneos 0 4,121,075
Gain (loss) on equity investment in affiliated entities 551,657 (9,298,443)
Share of net loss in Geneos 434,387 901,757
Net unrealized loss on available-for-sale equity securities 711,465 691,458
Non-cash lease expense 567,882 517,865
Unrealized transaction gain on foreign-currency denominated debt (176,927) (474,071)
Changes in operating assets and liabilities:    
Accounts receivable 5,431,637 (2,813,086)
Accounts receivable from affiliated entities (219,159) 865,832
Prepaid expenses and other current assets (51,944,060) (3,084,082)
Prepaid expenses and other current assets from affiliated entities (197,059) (1,330,601)
Other assets 24,126,582 116,242
Accounts payable and accrued expenses 8,891,770 (732,774)
Accrued clinical trial expenses 465,819 2,882,486
Accounts payable and accrued expenses due to affiliated entities 1,130,877 4,634
Deferred revenue 55,074 (92,426)
Deferred revenue from affiliated entities (6,250) 62,500
Operating lease right-of-use assets and liabilities, net (1,131,555) (1,022,951)
Grant funding liability (615,155) 4,265,023
Grant funding liability from affiliated entities (21,000) (63,050)
Other liabilities 6,478 29,686
Net cash used in operating activities (131,326,659) (52,604,208)
Cash flows from investing activities:    
Purchases of investments (307,857,113) (138,698,249)
Proceeds from sale or maturity of investments 83,466,967 47,455,067
Purchases of capital assets (418,734) (176,534)
Decrease in cash resulting from the deconsolidation of Geneos 0 2,774,851
Net cash used in investing activities (224,808,880) (94,194,567)
Cash flows from financing activities:    
Proceeds from issuance of common stock, net of issuance costs 162,105,030 329,960,855
Proceeds from stock option exercises 6,154,794 9,599,514
Taxes paid related to net share settlement of equity awards (3,915,160) (2,076,567)
Acquisition of non-controlling interest 0 2,379,969
Proceeds from Geneos issuance of note payable 0 171,620
Net cash provided by financing activities 164,344,664 340,035,391
Effect of exchange rate changes on cash and cash equivalents (11,941) 0
(Decrease) Increase in cash and cash equivalents (191,802,816) 193,236,616
Cash and cash equivalents, beginning of period 250,728,118 22,196,097
Cash and cash equivalents, end of period 58,925,302 215,432,713
Supplemental disclosures:    
Amounts accrued for purchases of property and equipment 0 1,620
Interest paid $ 544,315 $ 2,636,454